{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:53:30Z","timestamp":1789242810866,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","award":["CHCMU-2024-XKDF-1001"],"award-info":[{"award-number":["CHCMU-2024-XKDF-1001"]}],"id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22461160267"],"award-info":[{"award-number":["22461160267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22137002"],"award-info":[{"award-number":["22137002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22494700"],"award-info":[{"award-number":["22494700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"publisher","award":["cstc2021jcyj-msxmX0265"],"award-info":[{"award-number":["cstc2021jcyj-msxmX0265"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118668","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:02:22Z","timestamp":1770739342000},"page":"118668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development of the first-in-class RNF4 PROTAC degrader as potential therapeutics for hepatocellular carcinoma"],"prefix":"10.1016","volume":"307","author":[{"given":"Hui","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongkai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5637-4658","authenticated-orcid":false,"given":"Sanyong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejmech.2026.118668_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118668_bib2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118668_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102446","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"null","key":"10.1016\/j.ejmech.2026.118668_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/JHC.S300182","article-title":"Hepatocellular carcinoma: an overview of the changing landscape of treatment options","volume":"8","author":"Koulouris","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118668_bib5","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/liv.15052","article-title":"Paradigm shift in the treatment options of hepatocellular carcinoma","volume":"42","author":"Su","year":"2022","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118668_bib6","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in hepatocellular carcinoma therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","article-title":"Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma","volume":"23","author":"Chan","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1186\/s12885-021-08904-3","article-title":"Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database","volume":"21","author":"Ding","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118668_bib9","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118668_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/sj.emboj.7601839","article-title":"Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins","volume":"26","author":"Sun","year":"2007","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib11","article-title":"Stabilization of nuclear oncoproteins by RNF4 and the ubiquitin system in cancer","volume":"4","author":"Diefenbacher","year":"2016","journal-title":"Mole. Cell. Oncol."},{"key":"10.1016\/j.ejmech.2026.118668_bib12","series-title":"Plant Proteostasis","first-page":"83","article-title":"SUMO conjugation and SUMO chain formation by plant enzymes","author":"Tomanov","year":"2023"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118668_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jb\/mvac041","article-title":"Targeted protein degradation and drug discovery","volume":"172","author":"Naito","year":"2022","journal-title":"J. Biochem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118668_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/ijms22115796","article-title":"The E3 ubiquitin-protein ligase RNF4 promotes TNF-\u03b1-Induced cell death triggered by RIPK1","volume":"22","author":"Shimada","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113295","article-title":"RNF4 promotes tumorigenesis, therapy resistance of cholangiocarcinoma and affects cell cycle by regulating the ubiquitination degradation of p27kip1 in the nucleus","volume":"419","author":"Huang","year":"2022","journal-title":"Exp. Cell Res."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118668_bib16","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.230068","article-title":"RNF4 and USP7 cooperate in ubiquitin-regulated steps of DNA replication","volume":"13","author":"Chang","year":"2023","journal-title":"Open Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118668_bib17","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41594-024-01294-7","article-title":"Concerted SUMO-targeted ubiquitin ligase activities of TOPORS and RNF4 are essential for stress management and cell proliferation","volume":"31","author":"Liu","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118668_bib18","article-title":"SUMO-targeted ubiquitin ligases and their functions in maintaining genome stability","author":"Chang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s11658-024-00624-3","article-title":"Crosstalk between SUMOylation and other post-translational modifications in breast cancer","volume":"29","author":"Wei","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118668_bib20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41419-022-05262-1","article-title":"RNF4\u223cRGMb\u223cBMP6 axis required for osteogenic differentiation and cancer cell survival","volume":"13","author":"Novak","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41698-024-00724-5","article-title":"RNF4 mediated degradation of PDHA1 promotes colorectal cancer metabolism and metastasis","volume":"8","author":"Chen","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118668_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nsmb.2108","article-title":"Mechanism of ubiquitylation by dimeric RING ligase RNF4","volume":"18","author":"Plechanovov\u00e1","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118668_bib23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/cdd.2012.145","article-title":"RNF4 is required for DNA double-strand break repair in vivo","volume":"20","author":"Vyas","year":"2013","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118668_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/embr.201338369","article-title":"RNF4 interacts with both SUMO and nucleosomes to promote the DNA damage response","volume":"15","author":"Groocock","year":"2014","journal-title":"EMBO Rep."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118668_bib25","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1038\/s41388-022-02247-4","article-title":"RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma","volume":"41","author":"Lv","year":"2022","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118668_bib26","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118668_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118668_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118668_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"PROTAC 2.0: expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118668_bib30","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and Re-Emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J. Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2026.118668_bib31","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1021\/acs.jpcb.3c04710","article-title":"Landscape of in silico tools for modeling covalent modification of proteins: a review on computational covalent drug discovery","volume":"127","author":"Hasan","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2026.118668_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2019.02.008","article-title":"Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension","volume":"850","author":"Yu","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118668_bib33","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s10020-023-00736-0","article-title":"Neratinib for HER2-positive breast cancer with an overlooked option","volume":"29","author":"Guo","year":"2023","journal-title":"Mol. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118668_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.37349\/etat.2020.00018","article-title":"Current strategies for the design of PROTAC linkers: a critical review","volume":"1","author":"Troup","year":"2020","journal-title":"Explor Target Antitumor Ther."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118668_bib36","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118668_bib37","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/920161","article-title":"H2AX phosphorylation: its role in DNA damage response and cancer therapy","volume":"2010","author":"Podhorecka","year":"2010","journal-title":"J. Nucleic Acids"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:42:32Z","timestamp":1775482952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"alternative-id":["S0223523426001133"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118668","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of the first-in-class RNF4 PROTAC degrader as potential therapeutics for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118668"}}